Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models.
Gutmann M, Ertl IE, Herek P, Vician P, Pirker C, Nössing C, Brettner R, Lemberger U, Grausenburger R, Batlogg K, Baumfried O, Prantl I, Singh N, Laukhtina E, Oszwald A, Wasinger G, Compérat E, Berger W, Shariat SF, Englinger B. Gutmann M, et al. Among authors: brettner r. Eur Urol Oncol. 2024 Dec;7(6):1166-1170. doi: 10.1016/j.euo.2024.05.001. Epub 2024 May 16. Eur Urol Oncol. 2024. PMID: 38755094 Free article.
Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound.
Ertl IE, Lemberger U, Ilijazi D, Hassler MR, Bruchbacher A, Brettner R, Kronabitter H, Gutmann M, Vician P, Zeitler G, Koren A, Lardeau CH, Mohr T, Haitel A, Compérat E, Oszwald A, Wasinger G, Clozel T, Elemento O, Kubicek S, Berger W, Shariat SF. Ertl IE, et al. Among authors: brettner r. Eur Urol. 2022 Sep;82(3):261-270. doi: 10.1016/j.eururo.2022.03.009. Epub 2022 Apr 4. Eur Urol. 2022. PMID: 35393162 Free article.
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC.
Bianconi D, Herac M, Posch F, Schmeidl M, Unseld M, Kieler M, Brettner R, Müllauer L, Riedl J, Gerger A, Scheithauer W, Prager G. Bianconi D, et al. Among authors: brettner r. Ther Adv Med Oncol. 2020 Aug 18;12:1758835920928635. doi: 10.1177/1758835920928635. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32922518 Free PMC article.
SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment.
Bianconi D, Herac M, Spies D, Kieler M, Brettner R, Unseld M, Fürnkranz K, Famler B, Schmeidl M, Minichsdorfer C, Zielinski C, Heller G, Prager GW. Bianconi D, et al. Among authors: brettner r. Transl Oncol. 2019 Jan;12(1):15-23. doi: 10.1016/j.tranon.2018.08.019. Epub 2018 Sep 20. Transl Oncol. 2019. PMID: 30245304 Free PMC article.